Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease

Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease

Despite the curative potential of hematopoietic cell transplantation (HCT) for hematologic malignancies, graft-versus-host disease (GVHD) remains a substantial cause of morbidity and mortality, particularly if treatment is refractory. Treatment with additional immunosuppression including steroids of...

Full description

Bibliographic Details
Main Authors: Elizabeth Stenger, Cynthia R. Giver, Amelia Langston, Daniel Kota, Pankoj Kumar Das, Raghavan Chinnadurai, Jacques Galipeau, Edmund K. Waller, Muna Qayed
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Immunology
Subjects:
Mesechymal stromal cell
acute graft versus host disease (aGVHD)
chronic graft versus host disease (GVHD)
allogeneic transplant of haematopoietic stem cells
Hematologic malignancy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.959658/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.959658/full

Similar Items